View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2013	Oct. 31, 2013
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q3
Trading Symbol	DVAX
Entity Registrant Name	DYNAVAX TECHNOLOGIES CORP
Entity Central Index Key	0001029142
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		262,625,110

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 12,191	$ 7,599
Marketable securities available-for-sale	64,283	117,531
Accounts receivable	2,159	1,005
Prepaid expenses and other current assets	1,120	2,052
Total current assets	79,753	128,187
Property and equipment, net	8,454	7,965
Goodwill	2,532	2,475
Restricted cash	657	652
Other assets	302	473
Total assets	91,698	139,752
Current liabilities:
Accounts payable	1,289	2,166
Accrued liabilities	8,148	10,063
Deferred revenues	6,126	6,785
Total current liabilities	15,563	19,014
Deferred revenues, noncurrent	2,751	5,283
Other long-term liabilities	988	629
Total liabilities	19,302	24,926
Commitments and contingencies (Note 5)
Stockholders’ equity:
Preferred stock: $0.001 par value; 5,000 shares authorized and no shares issued and outstanding at September 30, 2013 and December 31, 2012
Common stock: $0.001 par value; 350,000 and 250,000 shares authorized at September 30, 2013 and December 31, 2012, respectively; 183,055 and 182,792 shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively	183	183
Additional paid-in capital	561,687	550,729
Accumulated other comprehensive loss:
Unrealized gain on marketable securities available-for-sale	22	45
Cumulative translation adjustment	(341)	(640)
Total accumulated other comprehensive loss	(319)	(595)
Accumulated deficit	(489,155)	(435,491)
Total stockholders’ equity	72,396	114,826
Total liabilities and stockholders’ equity	$ 91,698	$ 139,752

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Thousands	Sep. 30, 2013	Dec. 31, 2012
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000	5,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	350,000	250,000
Common stock, shares issued	183,055	182,792
Common stock, shares outstanding	183,055	182,792

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenues:
Collaboration revenue	$ 1,110	$ 1,050	$ 3,349	$ 3,602
Grant revenue	1,700	1,219	3,855	3,188
Service and license revenue	117	605	1,200	1,118
Total	2,927	2,874	8,404	7,908
Operating expenses:
Research and development	11,770	12,850	38,739	36,631
General and administrative	5,807	7,121	22,243	18,871
Unoccupied facility expense	918		918
Total operating expenses	18,495	19,971	61,900	55,502
Loss from operations	(15,568)	(17,097)	(53,496)	(47,594)
Interest income	37	91	163	208
Interest expense	(24)	(589)	(83)	(1,765)
Other expense	(120)	(196)	(248)	(255)
Net loss	$ (15,675)	$ (17,791)	$ (53,664)	$ (49,406)
Basic and diluted net loss per share	$ (0.09)	$ (0.10)	$ (0.29)	$ (0.30)
Weighted-average shares used to compute basic and diluted net loss per share	183,022	177,870	182,960	167,039

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Net loss	$ (15,675)	$ (17,791)	$ (53,664)	$ (49,406)
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities available-for-sale	18	59	(23)	32
Cumulative translation adjustment	473	249	299	38
Other comprehensive income	491	308	276	70
Total comprehensive loss	$ (15,184)	$ (17,483)	$ (53,388)	$ (49,336)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Operating activities
Net loss	$ (53,664)	$ (49,406)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	986	898
Gain on disposal of property and equipment	4	6
Accretion of discounts and amortization of premiums of marketable securities	692	970
Interest associated with long-term note payable to Holdings		1,642
Unoccupied facility expense	918
Stock compensation expense	10,847	6,294
Changes in operating assets and liabilities:
Accounts receivable	(1,154)	5,842
Prepaid expenses and other current assets	932	(1,289)
Restricted cash and other assets	166	(74)
Accounts payable	(877)	(462)
Accrued liabilities and other long term liabilities	(2,489)	1,011
Deferred revenues	(3,191)	(1,649)
Net cash used in operating activities	(46,830)	(36,217)
Investing activities
Purchases of marketable securities	(48,573)	(169,634)
Proceeds from maturities of marketable securities	101,105	127,085
Purchases of property and equipment, net	(1,316)	(1,727)
Net cash provided by (used in) investing activities	51,216	(44,276)
Financing activities
Payments and proceeds from issuances of common stock and warrants, net of issuance costs	(143)	71,124
Proceeds from exercise of stock options and restricted stock awards	30	1,789
Proceeds from employee stock purchase plan	224	307
Net cash provided by financing activities	111	73,220
Effect of exchange rate on cash and cash equivalents	95	(18)
Net increase (decrease) in cash and cash equivalents	4,592	(7,291)
Cash and cash equivalents at beginning of year	7,599	31,941
Cash and cash equivalents at end of year	12,191	24,650
Non-cash investing and financing activities:
Disposal of fully depreciated property and equipment	8	29
Net change in unrealized gain on marketable securities	$ (23)	$ 32

Organization and Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2013

Organization and Summary of Significant Accounting Policies

1. Organization and Summary of Significant Accounting Policies

Dynavax Technologies Corporation (“we,” “our,” “us,” Dynavax” or the “Company”), a clinical-stage biopharmaceutical company that discovers and develops novel products to prevent and treat infectious and inflammatory diseases and cancer. Our lead product candidate is HEPLISAV™, a hepatitis B vaccine product candidate in Phase 3 development.

In addition to HEPLISAV, our pipeline comprises clinical-stage product candidates including an autoimmune program partnered with GlaxoSmithKline, an asthma program partnered with AstraZeneca AB and a cancer immunotherapy program as well as a preclinical development program utilizing nanoparticle adjuvant technology. We compete with pharmaceutical companies, biotechnology companies, academic institutions and research organizations in developing therapies to prevent or treat infectious and inflammatory diseases and cancer.

Basis of Presentation

Our accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X. In our opinion, these unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, which we consider necessary to fairly state our financial position and the results of our operations and cash flows. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted. Interim-period results are not necessarily indicative of results of operations or cash flows for a full-year period or any other interim-period. The condensed consolidated balance sheet at December 31, 2012, has been derived from audited financial statements at that date, but excludes disclosures required by GAAP for complete financial statements.

The unaudited condensed consolidated financial statements and these notes should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2012, as filed with the Securities and Exchange Commission (the “SEC”).

The unaudited condensed consolidated financial statements include the accounts of Dynavax and our wholly-owned subsidiaries, Rhein Biotech GmbH (“Rhein” or “Dynavax Europe”) and Dynavax International, B.V. All significant intercompany accounts and transactions have been eliminated. We operate in one business segment, which is the discovery and development of biopharmaceutical products.

Liquidity and Financial Condition

We have incurred significant operating losses and negative cash flows from operations since our inception. As of September 30, 2013, we had cash, cash equivalents and marketable securities of $76.5 million. We currently estimate that we have sufficient cash resources to meet our anticipated cash needs through at least the next 12 months based on cash, cash equivalents and marketable securities on hand as of September 30, 2013 and anticipated revenues and funding from existing agreements.

We expect to continue to spend substantial funds in connection with the development and manufacturing of our product candidates, particularly HEPLISAV, various human clinical trials for our product candidates and protection of our intellectual property. In order to continue development of our product candidates, including HEPLISAV, and depending upon the cost and timing of an additional clinical study for HEPLISAV, we may need to raise additional funds. This may occur through strategic alliance and licensing arrangements and/or future public or private financings. Sufficient additional funding may not be available on acceptable terms, or at all. Additional equity financings, if completed, could result in significant dilution or otherwise adversely affect the rights of existing shareholders. If adequate funds are not available in the future, we may need to delay, reduce the scope of or put on hold the HEPLISAV program or our other development programs while we seek strategic alternatives.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. Actual results may differ materially from these estimates and assumptions. On an ongoing basis, we evaluate our estimates, including those related to revenue recognition, research and development activities, stock-based compensation, asset impairment, contingencies and the valuation of certain liabilities.

Summary of Significant Accounting Policies

There have been no significant changes in our significant accounting policies during the nine months ended September 30, 2013, as compared with those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2012.

Revenue Recognition

Our revenues consist of amounts earned from collaborations, grants and fees from services and licenses. We enter into license and manufacturing agreements and collaborative research and development arrangements with pharmaceutical and biotechnology partners that may involve multiple deliverables. Our arrangements may include one or more of the following elements: upfront license payments, cost reimbursement for the performance of research and development activities, milestone payments, other contingent payments, contract manufacturing service fees, royalties and license fees. Each deliverable in the arrangement is evaluated to determine whether it meets the criteria to be accounted for as a separate unit of accounting or whether it should be combined with other deliverables. In order to account for the multiple-element arrangements, the Company identifies the deliverables included within the arrangement and evaluates which deliverables represent separate units of accounting. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. We recognize revenue when there is persuasive evidence that an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable and collectability is reasonably assured.

On January 1, 2011, we adopted on a prospective basis Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2009-13, Multiple-Deliverable Revenue Arrangements, which amends the criteria related to identifying separate units of accounting and provides guidance on whether multiple deliverables exist, how an arrangement should be separated and the consideration allocated.

Non-refundable upfront fees received for license and collaborative agreements entered into prior to January 1, 2011 and other payments under collaboration agreements where we have continuing performance obligations related to the payments are deferred and recognized over our expected performance period. Revenue is recognized on a ratable basis, unless we determine that another methodology is more appropriate, through the date at which our performance obligations are completed. Management makes its best estimate of the period over which we expect to fulfill our performance obligations, which may include clinical development activities. Given the uncertainties of research and development collaborations, significant judgment is required to determine the duration of the performance period. We recognize cost reimbursement revenue under collaborative agreements as the related research and development costs are incurred, as provided for under the terms of these agreements.

On January 1, 2011, we elected to prospectively adopt the milestone method as described in FASB ASU 2010-17, Milestone Method of Revenue Recognition. Under the milestone method, contingent consideration received from the achievement of a substantive milestone is recognized in its entirety in the period in which the milestone is achieved. A milestone is defined as an event having all of the following characteristics: (i) there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved, (ii) the event can only be achieved based in whole or in part on either the entity’s performance or a specific outcome resulting from the entity’s performance and (iii) if achieved, the event would result in additional payments being due to the entity.

Our license and collaboration agreements with our partners provide for payments to be paid to us upon the achievement of development milestones. Given the challenges inherent in developing biologic products, there is substantial uncertainty whether any such milestones will be achieved at the time we entered into these agreements. In addition, we evaluate whether the development milestones meet the criteria to be considered substantive. The conditions include: (i) the development work is contingent on either of the following: (a) the vendor’s performance to achieve the milestone or (b) the enhancement of the value of the deliverable item or items as a result of a specific outcome resulting from the vendor’s performance to achieve the milestone; (ii) it relates solely to past performance and; (iii) it is reasonable relative to all the deliverable and payment terms within the arrangement. As a result of our analysis, we consider our development milestones to be substantive and, accordingly, we expect to recognize as revenue future payments received from such milestones as we achieve each milestone.

Milestone payments that are contingent upon the achievement of substantive at-risk performance criteria are recognized in full upon achievement of those milestone events in accordance with the terms of the agreement and assuming all other revenue recognition criteria have been met. All revenue recognized to date under our collaborative agreements has been nonrefundable.

Our license and collaboration agreements with certain partners also provide for contingent payments to be paid to us based solely upon the performance of our partner. For such contingent payments we expect to recognize the payments as revenue upon receipt, provided that collection is reasonably assured and the other revenue recognition criteria have been satisfied.

Revenues from manufacturing services are recognized upon meeting the criteria for substantial performance and acceptance by the customer.

Revenue from royalty payments is contingent on future sales activities by our licensees. As a result, we recognize royalty revenue when reported by our licensees and when collection is reasonably assured.

Revenue from government and private agency grants are recognized as the related research expenses are incurred and to the extent that funding is approved. Additionally, we recognize revenue based on the facilities and administrative cost rate reimbursable per the terms of the grant awards.

Recent Accounting Pronouncements

In February 2013, the FASB issued ASU 2013-02, “Reporting of Amounts Reclassified out of Accumulated Other Comprehensive Income.” This ASU expands the presentation of changes in accumulated other comprehensive income. The new guidance requires an entity to disaggregate the total change of each component of other comprehensive income either on the face of the statement of operations or as a separate disclosure in the financial statement footnotes. ASU 2013-02 is effective for fiscal years beginning after December 15, 2012. The Company adopted this guidance in the first quarter of 2013 and the adoption did not have any impact on our financial position, results of operations or cash flows as there were no amounts reclassified out of accumulated other comprehensive income during the periods ended September 30, 2013 and 2012.

Fair Value Measurements

9 Months Ended

Sep. 30, 2013

Fair Value Measurements

2. Fair Value Measurements

The Company defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

Level 1—Quoted prices in active markets for identical assets or liabilities;
Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and
Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Recurring Fair Value Measurements

The following table represents the fair value hierarchy for our financial assets measured at fair value on a recurring basis as of September 30, 2013 and December 31, 2012 (in thousands):

	Level 1
September 30, 2013
Money market funds	$	9,598	$	—	$	—	$	9,598
U.S. government agency securities		—		62,283		—		62,283
U.S. treasury securities		—		2,500		—		2,500
Total	$	9,598	$	64,783	$	—	$	74,381

	Level 1			Level 2			Level 3			Total
December 31, 2012
Money market funds	$	3,140	$		—	$		—	$		3,140
U.S. government agency securities		—			119,233			—			119,233
U.S. treasury securities		—			500			—			500
Municipal securities		—			715			—			715
Total	$	3,140	$		120,448	$		—	$		123,588

Money market funds are highly liquid investments and are actively traded. The pricing information on these investment instruments is readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 of the fair value hierarchy.

U.S. Government agency securities, U.S. treasury securities and municipal securities are measured at fair value using Level 2 inputs. We review trading activity and pricing for these investments as of each measurement date. When sufficient quoted pricing for identical securities is not available, we use market pricing and other observable market inputs for similar securities obtained from various third party data providers. These inputs represent quoted prices for similar assets in active markets or these inputs have been derived from observable market data. This approach results in the classification of these securities as Level 2 of the fair value hierarchy.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Cash, cash equivalents and marketable securities

9 Months Ended

Sep. 30, 2013

Cash, cash equivalents and marketable securities

3. Cash, cash equivalents and marketable securities

The following is a summary of cash, cash equivalents and marketable securities available-for-sale as of September 30, 2013 and December 31, 2012 (in thousands):

	Amortized Cost
September 30, 2013
Cash and cash equivalents:
Cash	$	2,093	$	—	$	—		$	2,093
Money market funds		9,598		—		—			9,598
U.S. government agency securities		500		—		—			500
Total cash and cash equivalents		12,191		—		—			12,191
Marketable securities available-for-sale:
U.S. treasury securities		2,500		—		—			2,500
U.S. government agency securities		61,761		22		—			61,783
Total marketable securities available-for-sale		64,261		22		—			64,283
Total cash, cash equivalents and marketable securities	$	76,452	$	22	$	—		$	76,474
December 31, 2012
Cash and cash equivalents:
Cash	$	1,542	$	—	$	—		$	1,542
Money market funds		3,140		—		—			3,140
Municipal securities		2,202		—		—			2,202
U.S. government agency securities		715		—		—			715
Total cash and cash equivalents		7,599		—		—			7,599
Marketable securities available-for-sale:
U.S. government agency securities		116,986		46		(1	)		117,031
U.S. treasury securities		500		—		—			500
Total marketable securities available-for-sale		117,486		46		(1	)		117,531
Total cash, cash equivalents and marketable securities	$	125,085	$	46	$	(1	)	$	125,130

The following is a summary of the amortized cost and estimated fair value of marketable securities available-for-sale, by contractual maturity (in thousands):

	September 30, 2013
	Amortized Cost		Estimated Fair Value
Mature in one year or less	$	55,761	$	55,778
Mature after one year through two years		8,500		8,505
	$	64,261	$	64,283

We have classified our entire investment portfolio as available-for-sale. We view our available-for-sale portfolio as available for use in current operations and accordingly have classified all investments as short-term. Available-for-sale securities are carried at fair value based on inputs that are observable, either directly or indirectly, such as quoted market prices for similar securities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the securities with unrealized gains and losses included in accumulated other comprehensive income (loss) in stockholders’ equity. Realized gains and losses and declines in value, if any, judged to be other than temporary on available-for-sale securities are included in interest income or expense. The cost of securities sold is based on the specific identification method. Management assesses whether declines in the fair value of investment securities are other than temporary. In determining whether a decline is other than temporary, management considers the following factors:

Whether the investment has been in a continuous realized loss position for over 12 months;
the duration to maturity of our investments;
our intention to hold the investments to maturity and if it is not more likely than not that we will be required to sell the investment before recovery of the amortized cost basis;
the credit rating, financial condition and near-term prospects of the issuer; and
the type of investments made.

To date, there have been no declines in fair value that have been identified as other than temporary.

Financing Agreements

9 Months Ended

Sep. 30, 2013

Financing Agreements

4. Financing Agreements

On March 29, 2013, we entered into an At Market Issuance Sales Agreement (the “Agreement”) with MLV & Co. LLC (“MLV”) under which we may offer and sell our common stock having aggregate sales proceeds of up to $50,000,000 from time to time through MLV as our sales agent. Sales of our common stock through MLV, if any, will be made by means of ordinary brokers’ transactions on the NASDAQ Capital Market or otherwise at market prices prevailing at the time of sale, in block transactions, or as otherwise agreed upon by us and MLV. MLV will use commercially reasonable efforts to sell our common stock from time to time, based upon instructions from us (including any price, time or size limits or other customary parameters or conditions we may impose). We will pay MLV a commission of up to 3.0% of the gross sales proceeds of any common stock sold through MLV under the Agreement. No sales of our common stock have taken place under this Agreement as of September 30, 2013.

Commitments and Contingencies

9 Months Ended

Sep. 30, 2013

Commitments and Contingencies

5. Commitments and Contingencies

We lease our facilities in Berkeley, California (“Berkeley Lease”) and Düsseldorf, Germany (“Düsseldorf Lease”) under operating leases that expire in June 2018 and March 2023, respectively. The Berkeley Lease provides for periods of escalating rent. The total cash payments over the life of the lease are divided by the total number of months in the lease period and the average rent is charged to expense each month during the lease period. We entered into sublease agreements under the Düsseldorf Lease for a certain portion of the leased space. The sublease income is offset against our rent expense.

During September 2013, we decided not to occupy a portion of our facility in Berkeley, California. As a result, we recorded a one-time estimated unoccupied facility expense of $0.9 million for the three and nine months ended September 30, 2013, representing the present value of the rent payments and other costs associated with the lease, net of estimated sublease income, for the remaining life of the operating lease.

Total net rent expense related to our operating leases for the three months ended September 30, 2013 and 2012, was $0.6 million and $0.4 million, respectively. Total net rent expense related to our operating leases for the nine months ended September 30, 2013 and 2012, was $1.4 million and $1.3 million, respectively. Deferred rent was $0.6 million as of both September 30, 2013 and December 31, 2012.

Future minimum payments under the non-cancelable portion of our operating leases at September 30, 2013, excluding payments from sublease agreements, are as follows (in thousands):

Years ending December 31,
2013 (remaining months)	$	559
2014		2,223
2015		2,272
2016		2,323
2017		2,372
Thereafter		3,794
Total	$	13,543

In addition to the non-cancelable commitments included above, we have entered into contractual arrangements that obligate us to make payments to the contractual counterparties upon the occurrence of future events. In addition, in the normal course of operations, we have entered into license and other agreements and intend to continue to seek additional rights relating to compounds or technologies in connection with our discovery, manufacturing and development programs. Under the terms of the agreements, we may be required to pay future up-front fees, milestones, royalties on net sales of products originating from the licensed technologies, if any, or other payments contingent upon the occurrence of future events that cannot reasonably be estimated.

We rely on research institutions, contract research organizations, clinical investigators as well as clinical and commercial material manufacturers of our product candidates. As of September 30, 2013, under the terms of our agreements, we are obligated to make future payments as services are provided of approximately $6.3 million through 2015. These agreements are terminable by us upon written notice. Generally, we are liable only for actual effort expended by the organizations at any point in time during the contract through the notice period.

Under the terms of our exclusive license agreements with The Regents of the University of California, as amended, for certain technology and related patent rights and materials, we pay annual license or maintenance fees and will be required to pay milestones and royalties on net sales, if any, of certain products originating from the licensed technologies.

Collaborative Research and Development Agreements

9 Months Ended

Sep. 30, 2013

Collaborative Research and Development Agreements

6. Collaborative Research and Development Agreements

GlaxoSmithKline

In December 2008, we entered into a worldwide strategic alliance with GSK to discover, develop and commercialize toll-like receptor (“TLR”) inhibitors. Under the terms of the arrangement, we agreed to conduct research and early clinical development in up to four programs: the Lead TLR 7/9 program, a Follow-On TLR 7/9 program, and up to two other TLR programs. In 2011 we began development of a TLR8 program as one of the two additional programs under the collaboration.

We are currently conducting a Phase 1 clinical trial in the Lead TLR 7/9 program with DV1179 in systemic lupus erythematosus patients. The Company is not currently performing any activities on the Follow-On TLR 7/9 program or the TLR8 program. GSK has not yet chosen to initiate development of the remaining program under the agreement.

GSK can exercise its exclusive option to license each program. If GSK exercises an option, GSK would carry out further development and commercialization of the corresponding products. If GSK exercises their option on the Lead TLR 7/9 program, then we are eligible to receive payments of up to approximately $125 million, comprised of contingent option exercise payments and additional payments based on GSK’s achievement of certain development, regulatory and commercial objectives.

We are also eligible to receive up to $60 million if aggregate worldwide annual net sales milestones are achieved and tiered royalties ranging from the mid–single digit to mid-teens on sales of any products originating from the collaboration. We have retained an option to co-develop and co-promote one product under this agreement.

We received an initial payment of $10 million in 2008. The deliverables under this arrangement did not have stand-alone value and so did not qualify as separate units of accounting. In 2011, we earned and recognized $12 million in substantive development milestone payments related to the initiation of Phase I and proof-of-mechanism clinical trials of DV1179 in systemic lupus erythematosus patients. In 2011, we earned and recognized $3 million in substantive development milestone payments related to the initiation of development of theTLR8 program.

Revenue from the initial payment from GSK was deferred and is being recognized over the expected period of performance under the agreement, which is estimated to be seven years.

The following table summarizes the revenues recognized under our agreement with GSK (in thousands):

	Three months Ended September 30,										Nine months Ended September 30,
	2013					2012					2013					2012
Initial payment	$		357			$		357			$		1,071			$		1,071

As of September 30, 2013 and December 31, 2012, deferred revenue relating to the initial payment was $3.2 million and $4.2 million, respectively.

Absent early termination, the agreement will expire when all of GSK’s payment obligations expire. Either party may terminate the agreement early upon written notice if the other party commits an uncured material breach of the agreement. Either party may terminate the agreement in the event of insolvency of the other party. GSK also has the option to terminate the agreement without cause upon prior written notice within a specified window of time dependent upon the stage of clinical development of the programs.

AstraZeneca

In September 2006, we entered into a three-year research collaboration and license agreement with AstraZeneca for the discovery and development of TLR9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease.

In October 2011, we amended our agreement with AstraZeneca to provide that we will conduct initial clinical development of AZD 1419. Under the terms of the amended agreement, AstraZeneca will fund all program expenses to cover the cost of development activities through Phase 2a, estimated to total approximately $20 million. We received an initial payment of $3 million to begin the clinical development program. In the first quarter of 2012, we received a $2.6 million payment to advance AZD1419 into preclinical toxicology studies and these toxicology studies were completed in the third quarter of 2012. We and AstraZeneca have agreed to advance AZD 1419 towards a Phase 1 clinical trial, which resulted in a development funding payment of $6 million, received in the fourth quarter of 2012. If AstraZeneca chooses to advance the program following completion of Phase 2a, we will receive a $20 million milestone payment and AstraZeneca will retain its rights to develop the candidate therapy and to commercialize the resulting asthma product. We are eligible to receive additional milestone payments, which we have determined to be substantive milestones, of up to approximately $100 million, based on the achievement of certain development and regulatory objectives. Additionally, upon commercialization, we are eligible to receive tiered royalties ranging from the mid to high single-digits based on product sales of any products originating from the collaboration. We have the option to co-promote in the United States products arising from the collaboration, if any. AstraZeneca has the right to sublicense its rights upon our prior consent.

Revenue from the initial payment was deferred and is being recognized over the expected period of performance under the agreement, which is approximately 50 months. Revenue from the development funding payment is being recognized as the development work is performed.

The following table summarizes the revenues earned under our agreement with AstraZeneca (in thousands):

	Three Months Ended September 30,
	2013		2012		2013		2012
Initial payment	$	180	$	180	$	540	$	540
Performance of research activities		573		513		1,738		1,991
Total	$	753	$	693	$	2,278	$	2,531

As of September 30, 2013 and December 31, 2012, total deferred revenue from the initial payment and development funding payments was $5.7 million and $7.7 million, respectively.

Absent early termination, the agreement will expire when all of AstraZeneca’s payment obligations expire. AstraZeneca has the right to terminate the agreement at any time upon prior written notice and either party may terminate the agreement early upon written notice if the other party commits an uncured material breach of the agreement.

National Institutes of Health (“NIH”) and Other Funding

We have been awarded various grants from the NIH and the NIH’s National Institute of Allergy and Infectious Disease (“NIAID”) in order to fund research. The awards are related to specific research objectives and we earn revenue as the related research expenses are incurred. We have earned revenue during the periods ended September 30, 2013 and 2012 from the following awards:

September 2013, NIH awarded us $0.2 million to fund research in developing TLR antagonists for therapy of hepatic fibrosis and cirrhosis.
June 2012, NIH awarded us $0.6 million to fund research in screening for inhibitors of TLR8 for treatment of autoimmune diseases.
May 2012, NIH awarded us $0.4 million to fund development of TLR8 inhibitors for treatment of rheumatoid arthritis.
July 2011, NIH awarded us $0.6 million to fund research in preclinical models of skin autoimmune inflammation.
August 2010, NIAID awarded us a grant to take a systems biology approach to study the differences between individuals who do or do not respond to vaccination against the hepatitis B virus. This study will be one of several projects conducted under a grant to the Baylor Institute of Immunology Research in Dallas as part of the Human Immune Phenotyping Centers program. We have been awarded a total of $1.4 million under this grant.
July 2010, NIH awarded us $0.6 million to explore the feasibility of developing a universal vaccine to prevent infection by human papilloma virus.
September 2008, NIAID awarded us a five-year $17 million contract to develop our ISS technology using TLR9 agonists as vaccine adjuvants. The contract supports adjuvant development for anthrax as well as other disease models.

The following table summarizes the revenues recognized under the various arrangements with the NIH and NIAID (in thousands):

	Three Months Ended September 30,
	2013		2012		2013		2012
NIAID contracts	$	1,465	$	1,100	$	3,125	$	2,840
All other NIH contracts		235		119		730		348
Total grant revenue	$	1,700	$	1,219	$	3,855	$	3,188

Net Loss Per Share

9 Months Ended

Sep. 30, 2013

Net Loss Per Share

7. Net Loss Per Share

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period and dilutive potential common shares using the treasury-stock method. For purposes of this calculation, common stock subject to repurchase by us, outstanding options and warrants are considered to be dilutive potential common shares and are only included in the calculation of diluted net loss per share when their effect is dilutive. Outstanding warrants, stock options and stock awards to purchase approximately 31,100,000 and 34,400,000 shares of common stock as of September 30, 2013 and 2012, respectively, were excluded from the calculation of diluted net loss per share for the quarters ended September 30, 2013 and 2012, because the effect of their inclusion would have been anti-dilutive.

Stockholders' Equity

9 Months Ended

Sep. 30, 2013

Stockholders' Equity

8. Stockholders’ Equity

On May 29, 2013, the stockholders of the Company approved an amendment to the Company’s 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under the plan by 10,000,000.

Option activity under our stock-based compensation plans during the nine months ended September 30, 2013 was as follows (in thousands except per share amounts):


Balance as of December 31, 2012	13,806		$	3.38
Options granted	5,542			2.71
Options exercised	(74	)		1.41
Options cancelled:
Options forfeited (unvested)	(2,028	)		3.33
Options cancelled (vested)	(381	)		3.56
Balance as of September 30, 2013	16,865		$	3.17	5.35	$	310
Vested and expected to vest as of September 30, 2013	16,272		$	3.18	4.97	$	310
Exercisable as of September 30, 2013	10,977		$	3.35	3.37	$	307

Restricted stock unit activity under our stock-based compensation plans during the nine months ended September 30, 2013 was as follows (in thousands except per share amounts):

			Weighted-Average Grant-Date Fair Value
Balance as of December 31, 2012	1,755		$	4.23
Granted	250			1.23
Vested	—			—
Forfeited or expired	(230	)		4.23
Balance as of September 30, 2013	1,775		$	3.81

The aggregate intrinsic value of the restricted stock units outstanding as of September 30, 2013, based on our stock price on that date, was $2.1 million.

As of September 30, 2013, approximately 2,600,000 shares underlying stock options and restricted stock units awards with performance-based vesting criteria were outstanding.

Under our stock-based compensation plans, option awards generally vest over a four-year period contingent upon continuous service and expire ten years from the date of grant (or earlier upon termination of continuous service). The fair value-based measurement of each option is estimated on the date of grant using the Black-Scholes option valuation model.

The fair value-based measurements and weighted-average assumptions used in the calculations of these measurements are as follows:

	Stock Options						Stock Options						Employee Stock Purchase Plan
	Three Months Ended September 30,						Nine Months Ended September 30,						Nine Months Ended September 30,
	2013			2012			2013			2012			2013			2012
Weighted-average fair value	$	1.15		$	3.34		$	2.43		$	3.30		$	0.93		$	3.80
Risk-free interest rate		1.9	%		0.6	%		1.1	%		0.5	%		0.2	%		0.2	%
Expected life (in years)		5.6			4.0			5.9			4.0			1.3			1.0
Volatility		1.5			1.6			1.4			1.6			0.8			1.6

Expected volatility is based on historical volatility of our stock price. The expected life of options granted is estimated based on historical option exercise and employee termination data, giving consideration to options that have not yet completed a full life cycle. Our senior management, who hold a majority of the options outstanding, and other employees were grouped and considered separately for valuation purposes. The expected life of the options for senior management is six years and for other employees five and a half years. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The dividend yield is zero percent for all years and is based on our history and expectation of dividend payouts. All stock option awards to non-employees are accounted for at the fair value of the consideration received or the fair value of the equity instrument issued, as calculated using the Black-Scholes model.

Compensation expense is based on awards ultimately expected to vest and reflects estimated forfeitures. For equity awards with time-based vesting, the fair value-based measurement is amortized to expense on a straight-line basis over the vesting periods. For equity awards with performance-based vesting criteria, the fair value-based measurement is amortized to expense over the remaining vesting period commencing when the achievement of the vesting criteria becomes probable.

We recognized stock-based compensation expense of $2.8 million and $1.9 million for the three months ended September 30, 2013 and 2012, respectively. Stock-based compensation expense for the three months ended September 30, 2013 includes $1.0 million related to severance arrangements. We recognized stock-based compensation expense of $10.8 million and $6.3 million for the nine months ended September 30, 2013 and 2012, respectively. Stock-based compensation during the nine months ended September 30, 2013 included $5.1 million related to severance arrangements. The Company recorded stock-based compensation expense for awards to non-employees of $0.4 million for the nine months ended September 30, 2013.

The components of stock-based compensation expense were (in thousands):

	Three Months Ended September 30,
	2013		2012		2013		2012
Research and development	$	1,001	$	824	$	3,351	$	2,565
General and administrative		1,844		1,079		7,496		3,729
Total	$	2,845	$	1,903	$	10,847	$	6,294

As of September 30, 2013, the total unrecognized compensation cost related to non-vested equity awards including all awards with time-based vesting amounted to $12.1 million, which is expected to be recognized over the remaining weighted-average vesting period of 2.93 years. Additionally, as of September 30, 2013, the total unrecognized compensation cost related to equity awards with performance-based vesting criteria not deemed probable of vesting amounted to $5.0 million.

Employee Stock Purchase Plan

As of September 30, 2013, 996,000 shares have been reserved and approved for issuance under the Purchase Plan, subject to adjustment for a stock split, any future stock dividend or other similar change in our common stock or capital structure. To date, employees have acquired 828,414 shares of our common stock under the Purchase Plan including 129,690 shares during the nine months ended September 30, 2013. As of September 30, 2013, 167,586 shares of our common stock remained available for future purchases.

Warrants

As of September 30, 2013, warrants to purchase an aggregate of approximately 12,500,000 shares of our common stock were outstanding. The warrants are exercisable at a weighted average price of $1.96 per share. During the nine months ended September 30, 2013 and September 30, 2012, warrants were exercised to purchase an aggregate of approximately 84,000 and 4,700,000 shares of our common stock, respectively.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Subsequent Events

9 Months Ended

Sep. 30, 2013

Subsequent Events

9. Subsequent Events

On October 30, 2013, we sold 79,570,000 shares of our common stock at a price of $1.075 per share and 43,430 shares of the Company’s Series B Convertible Preferred Stock (“Series B”) at a price of $1,075.00, in separate, concurrent underwritten public offerings. The sale of common stock and Series B resulted in aggregate net proceeds to us of approximately $125 million after deducting estimated commissions and offering expenses.

Organization and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2013
Basis of Presentation	Basis of Presentation Our accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X. In our opinion, these unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, which we consider necessary to fairly state our financial position and the results of our operations and cash flows. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted. Interim-period results are not necessarily indicative of results of operations or cash flows for a full-year period or any other interim-period. The condensed consolidated balance sheet at December 31, 2012, has been derived from audited financial statements at that date, but excludes disclosures required by GAAP for complete financial statements. The unaudited condensed consolidated financial statements and these notes should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2012, as filed with the Securities and Exchange Commission (the “SEC”). The unaudited condensed consolidated financial statements include the accounts of Dynavax and our wholly-owned subsidiaries, Rhein Biotech GmbH (“Rhein” or “Dynavax Europe”) and Dynavax International, B.V. All significant intercompany accounts and transactions have been eliminated. We operate in one business segment, which is the discovery and development of biopharmaceutical products.
Liquidity and Financial Condition	Liquidity and Financial Condition We have incurred significant operating losses and negative cash flows from operations since our inception. As of September 30, 2013, we had cash, cash equivalents and marketable securities of $76.5 million. We currently estimate that we have sufficient cash resources to meet our anticipated cash needs through at least the next 12 months based on cash, cash equivalents and marketable securities on hand as of September 30, 2013 and anticipated revenues and funding from existing agreements. We expect to continue to spend substantial funds in connection with the development and manufacturing of our product candidates, particularly HEPLISAV, various human clinical trials for our product candidates and protection of our intellectual property. In order to continue development of our product candidates, including HEPLISAV, and depending upon the cost and timing of an additional clinical study for HEPLISAV, we may need to raise additional funds. This may occur through strategic alliance and licensing arrangements and/or future public or private financings. Sufficient additional funding may not be available on acceptable terms, or at all. Additional equity financings, if completed, could result in significant dilution or otherwise adversely affect the rights of existing shareholders. If adequate funds are not available in the future, we may need to delay, reduce the scope of or put on hold the HEPLISAV program or our other development programs while we seek strategic alternatives.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. Actual results may differ materially from these estimates and assumptions. On an ongoing basis, we evaluate our estimates, including those related to revenue recognition, research and development activities, stock-based compensation, asset impairment, contingencies and the valuation of certain liabilities.
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies There have been no significant changes in our significant accounting policies during the nine months ended September 30, 2013, as compared with those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2012.
Revenue Recognition	Revenue Recognition Our revenues consist of amounts earned from collaborations, grants and fees from services and licenses. We enter into license and manufacturing agreements and collaborative research and development arrangements with pharmaceutical and biotechnology partners that may involve multiple deliverables. Our arrangements may include one or more of the following elements: upfront license payments, cost reimbursement for the performance of research and development activities, milestone payments, other contingent payments, contract manufacturing service fees, royalties and license fees. Each deliverable in the arrangement is evaluated to determine whether it meets the criteria to be accounted for as a separate unit of accounting or whether it should be combined with other deliverables. In order to account for the multiple-element arrangements, the Company identifies the deliverables included within the arrangement and evaluates which deliverables represent separate units of accounting. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. We recognize revenue when there is persuasive evidence that an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable and collectability is reasonably assured. On January 1, 2011, we adopted on a prospective basis Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2009-13, Multiple-Deliverable Revenue Arrangements, which amends the criteria related to identifying separate units of accounting and provides guidance on whether multiple deliverables exist, how an arrangement should be separated and the consideration allocated. Non-refundable upfront fees received for license and collaborative agreements entered into prior to January 1, 2011 and other payments under collaboration agreements where we have continuing performance obligations related to the payments are deferred and recognized over our expected performance period. Revenue is recognized on a ratable basis, unless we determine that another methodology is more appropriate, through the date at which our performance obligations are completed. Management makes its best estimate of the period over which we expect to fulfill our performance obligations, which may include clinical development activities. Given the uncertainties of research and development collaborations, significant judgment is required to determine the duration of the performance period. We recognize cost reimbursement revenue under collaborative agreements as the related research and development costs are incurred, as provided for under the terms of these agreements. On January 1, 2011, we elected to prospectively adopt the milestone method as described in FASB ASU 2010-17, Milestone Method of Revenue Recognition. Under the milestone method, contingent consideration received from the achievement of a substantive milestone is recognized in its entirety in the period in which the milestone is achieved. A milestone is defined as an event having all of the following characteristics: (i) there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved, (ii) the event can only be achieved based in whole or in part on either the entity’s performance or a specific outcome resulting from the entity’s performance and (iii) if achieved, the event would result in additional payments being due to the entity. Our license and collaboration agreements with our partners provide for payments to be paid to us upon the achievement of development milestones. Given the challenges inherent in developing biologic products, there is substantial uncertainty whether any such milestones will be achieved at the time we entered into these agreements. In addition, we evaluate whether the development milestones meet the criteria to be considered substantive. The conditions include: (i) the development work is contingent on either of the following: (a) the vendor’s performance to achieve the milestone or (b) the enhancement of the value of the deliverable item or items as a result of a specific outcome resulting from the vendor’s performance to achieve the milestone; (ii) it relates solely to past performance and; (iii) it is reasonable relative to all the deliverable and payment terms within the arrangement. As a result of our analysis, we consider our development milestones to be substantive and, accordingly, we expect to recognize as revenue future payments received from such milestones as we achieve each milestone. Milestone payments that are contingent upon the achievement of substantive at-risk performance criteria are recognized in full upon achievement of those milestone events in accordance with the terms of the agreement and assuming all other revenue recognition criteria have been met. All revenue recognized to date under our collaborative agreements has been nonrefundable. Our license and collaboration agreements with certain partners also provide for contingent payments to be paid to us based solely upon the performance of our partner. For such contingent payments we expect to recognize the payments as revenue upon receipt, provided that collection is reasonably assured and the other revenue recognition criteria have been satisfied. Revenues from manufacturing services are recognized upon meeting the criteria for substantial performance and acceptance by the customer. Revenue from royalty payments is contingent on future sales activities by our licensees. As a result, we recognize royalty revenue when reported by our licensees and when collection is reasonably assured. Revenue from government and private agency grants are recognized as the related research expenses are incurred and to the extent that funding is approved. Additionally, we recognize revenue based on the facilities and administrative cost rate reimbursable per the terms of the grant awards.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In February 2013, the FASB issued ASU 2013-02, “Reporting of Amounts Reclassified out of Accumulated Other Comprehensive Income.” This ASU expands the presentation of changes in accumulated other comprehensive income. The new guidance requires an entity to disaggregate the total change of each component of other comprehensive income either on the face of the statement of operations or as a separate disclosure in the financial statement footnotes. ASU 2013-02 is effective for fiscal years beginning after December 15, 2012. The Company adopted this guidance in the first quarter of 2013 and the adoption did not have any impact on our financial position, results of operations or cash flows as there were no amounts reclassified out of accumulated other comprehensive income during the periods ended September 30, 2013 and 2012.

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References + Details

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2013

Fair Value Hierarchy for Financial Assets Measured at Fair Value on Recurring Basis

The following table represents the fair value hierarchy for our financial assets measured at fair value on a recurring basis as of September 30, 2013 and December 31, 2012 (in thousands):

	Level 1
September 30, 2013
Money market funds	$	9,598	$	—	$	—	$	9,598
U.S. government agency securities		—		62,283		—		62,283
U.S. treasury securities		—		2,500		—		2,500
Total	$	9,598	$	64,783	$	—	$	74,381

	Level 1			Level 2			Level 3			Total
December 31, 2012
Money market funds	$	3,140	$		—	$		—	$		3,140
U.S. government agency securities		—			119,233			—			119,233
U.S. treasury securities		—			500			—			500
Municipal securities		—			715			—			715
Total	$	3,140	$		120,448	$		—	$		123,588

Cash, cash equivalents and marketable securities (Tables)

9 Months Ended

Sep. 30, 2013

Summary of Cash, Cash Equivalents and Marketable Securities Available-for-sale

The following is a summary of cash, cash equivalents and marketable securities available-for-sale as of September 30, 2013 and December 31, 2012 (in thousands):

	Amortized Cost
September 30, 2013
Cash and cash equivalents:
Cash	$	2,093	$	—	$	—		$	2,093
Money market funds		9,598		—		—			9,598
U.S. government agency securities		500		—		—			500
Total cash and cash equivalents		12,191		—		—			12,191
Marketable securities available-for-sale:
U.S. treasury securities		2,500		—		—			2,500
U.S. government agency securities		61,761		22		—			61,783
Total marketable securities available-for-sale		64,261		22		—			64,283
Total cash, cash equivalents and marketable securities	$	76,452	$	22	$	—		$	76,474
December 31, 2012
Cash and cash equivalents:
Cash	$	1,542	$	—	$	—		$	1,542
Money market funds		3,140		—		—			3,140
Municipal securities		2,202		—		—			2,202
U.S. government agency securities		715		—		—			715
Total cash and cash equivalents		7,599		—		—			7,599
Marketable securities available-for-sale:
U.S. government agency securities		116,986		46		(1	)		117,031
U.S. treasury securities		500		—		—			500
Total marketable securities available-for-sale		117,486		46		(1	)		117,531
Total cash, cash equivalents and marketable securities	$	125,085	$	46	$	(1	)	$	125,130

Summary of Amortized Cost and Estimated Fair Value of Marketable Securities Available-for-sale

The following is a summary of the amortized cost and estimated fair value of marketable securities available-for-sale, by contractual maturity (in thousands):

	September 30, 2013
	Amortized Cost		Estimated Fair Value
Mature in one year or less	$	55,761	$	55,778
Mature after one year through two years		8,500		8,505
	$	64,261	$	64,283

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details

Commitments and Contingencies (Tables)

9 Months Ended

Sep. 30, 2013

Future Minimum Payments Under Non-Cancelable Portion of Operating Leases

Future minimum payments under the non-cancelable portion of our operating leases at September 30, 2013, excluding payments from sublease agreements, are as follows (in thousands):

Years ending December 31,
2013 (remaining months)	$	559
2014		2,223
2015		2,272
2016		2,323
2017		2,372
Thereafter		3,794
Total	$	13,543

Collaborative Research and Development Agreements (Tables)

9 Months Ended

Sep. 30, 2013

Agreement With Gsk

Summary of Revenues Recognized by Major Customer

The following table summarizes the revenues recognized under our agreement with GSK (in thousands):

	Three months Ended September 30,										Nine months Ended September 30,
	2013					2012					2013					2012
Initial payment	$		357			$		357			$		1,071			$		1,071

Astra Zeneca

Summary of Revenues Recognized by Major Customer

The following table summarizes the revenues earned under our agreement with AstraZeneca (in thousands):

	Three Months Ended September 30,
	2013		2012		2013		2012
Initial payment	$	180	$	180	$	540	$	540
Performance of research activities		573		513		1,738		1,991
Total	$	753	$	693	$	2,278	$	2,531

National Institutes of Health

Summary of Revenues Recognized by Major Customer

The following table summarizes the revenues recognized under the various arrangements with the NIH and NIAID (in thousands):

	Three Months Ended September 30,
	2013		2012		2013		2012
NIAID contracts	$	1,465	$	1,100	$	3,125	$	2,840
All other NIH contracts		235		119		730		348
Total grant revenue	$	1,700	$	1,219	$	3,855	$	3,188

Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2013

Option Activity under Stock-Based Compensation Plans

Option activity under our stock-based compensation plans during the nine months ended September 30, 2013 was as follows (in thousands except per share amounts):


Balance as of December 31, 2012	13,806		$	3.38
Options granted	5,542			2.71
Options exercised	(74	)		1.41
Options cancelled:
Options forfeited (unvested)	(2,028	)		3.33
Options cancelled (vested)	(381	)		3.56
Balance as of September 30, 2013	16,865		$	3.17	5.35	$	310
Vested and expected to vest as of September 30, 2013	16,272		$	3.18	4.97	$	310
Exercisable as of September 30, 2013	10,977		$	3.35	3.37	$	307

Summary of Restricted Stock Units Activity

Restricted stock unit activity under our stock-based compensation plans during the nine months ended September 30, 2013 was as follows (in thousands except per share amounts):

			Weighted-Average Grant-Date Fair Value
Balance as of December 31, 2012	1,755		$	4.23
Granted	250			1.23
Vested	—			—
Forfeited or expired	(230	)		4.23
Balance as of September 30, 2013	1,775		$	3.81

Fair Value-Based Measurements and Weighted-Average Assumptions

The fair value-based measurements and weighted-average assumptions used in the calculations of these measurements are as follows:

	Stock Options						Stock Options						Employee Stock Purchase Plan
	Three Months Ended September 30,						Nine Months Ended September 30,						Nine Months Ended September 30,
	2013			2012			2013			2012			2013			2012
Weighted-average fair value	$	1.15		$	3.34		$	2.43		$	3.30		$	0.93		$	3.80
Risk-free interest rate		1.9	%		0.6	%		1.1	%		0.5	%		0.2	%		0.2	%
Expected life (in years)		5.6			4.0			5.9			4.0			1.3			1.0
Volatility		1.5			1.6			1.4			1.6			0.8			1.6

Stock-Based Compensation Expense

The components of stock-based compensation expense were (in thousands):

	Three Months Ended September 30,
	2013		2012		2013		2012
Research and development	$	1,001	$	824	$	3,351	$	2,565
General and administrative		1,844		1,079		7,496		3,729
Total	$	2,845	$	1,903	$	10,847	$	6,294

Organization and Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Product Information [Line Items]
Cash, cash equivalents and marketable securities	$ 76,500,000
Amount reclassified out of accumulated other comprehensive income	$ 0	$ 0

- Definition

Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.

+ References + Details

Fair Value Hierarchy for Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Sep. 30, 2013	Dec. 31, 2012
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Assets	$ 74,381	$ 123,588
Money market funds
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Assets	9,598	3,140
US Government Agencies Debt Securities
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Assets	62,283	119,233
US Treasury Securities
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Assets	2,500	500
Municipal Securities
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Assets		715
Fair Value, Inputs, Level 1
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Assets	9,598	3,140
Fair Value, Inputs, Level 1 \| Money market funds
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Assets	9,598	3,140
Fair Value, Inputs, Level 2
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Assets	64,783	120,448
Fair Value, Inputs, Level 2 \| US Government Agencies Debt Securities
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Assets	62,283	119,233
Fair Value, Inputs, Level 2 \| US Treasury Securities
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Assets	$ 2,500	500
Fair Value, Inputs, Level 2 \| Municipal Securities
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Assets		$ 715

Summary of Cash, Cash Equivalents and Marketable Securities Available-for-sale (Detail) - USD ($) $ in Thousands	Sep. 30, 2013	Dec. 31, 2012
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost	$ 76,452	$ 125,085
Unrealized Gains	22	46
Unrealized Losses		(1)
Estimated Fair Value	76,474	125,130
Cash and Cash Equivalents
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost	12,191	7,599
Estimated Fair Value	12,191	7,599
Cash and Cash Equivalents \| Cash
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost	2,093	1,542
Estimated Fair Value	2,093	1,542
Cash and Cash Equivalents \| Money market funds
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost	9,598	3,140
Estimated Fair Value	9,598	3,140
Cash and Cash Equivalents \| Municipal Securities
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost		2,202
Estimated Fair Value		2,202
Cash and Cash Equivalents \| US Government Agencies Debt Securities
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost	500	715
Estimated Fair Value	500	715
Available-for-sale Securities
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost	64,261	117,486
Unrealized Gains	22	46
Unrealized Losses		(1)
Estimated Fair Value	64,283	117,531
Available-for-sale Securities \| US Government Agencies Debt Securities
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost	61,761	116,986
Unrealized Gains	22	46
Unrealized Losses		(1)
Estimated Fair Value	61,783	117,031
Available-for-sale Securities \| US Treasury Securities
Cash Cash Equivalents And Marketable Securities [Line Items]
Amortized Cost	2,500	500
Estimated Fair Value	$ 2,500	$ 500

Summary of Amortized Cost and Estimated Fair Value of Marketable Securities Available-for-sale (Detail) $ in Thousands	Sep. 30, 2013 USD ($)
Amortized Cost
Mature in one year or less	$ 55,761
Mature after one year through two years	8,500
Total amortized cost	64,261
Estimated Fair Value
Mature in one year or less	55,778
Mature after one year through two years	8,505
Total estimated fair value	$ 64,283

Financing Agreements - Additional Information (Detail) - MLV - Maximum	1 Months Ended
	Mar. 29, 2013 USD ($)
Subsidiary Sale Of Stock [Line Items]
Common stock aggregate offering price	$ 50,000,000
Commission on gross sales proceeds of common stock	3.00%

Future Minimum Payments under Non-Cancelable Portion of Operating Leases (Detail) $ in Thousands	Sep. 30, 2013 USD ($)
Operating Leased Assets [Line Items]
2013 (remaining months)	$ 559
2014	2,223
2015	2,272
2016	2,323
2017	2,372
Thereafter	3,794
Total	$ 13,543

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Loss Contingencies [Line Items]
Rent expense, net	$ 600	$ 400	$ 1,400	$ 1,300
Deferred rent	600		600		$ 600
Future payments obligation			6,300
Unoccupied facility expense	$ 918		$ 918
CALIFORNIA
Loss Contingencies [Line Items]
Operating leases expiration date			2018-06
Dusseldorf, Germany (the "Dusseldorf Lease")
Loss Contingencies [Line Items]
Operating leases expiration date			2023-03

Collaborative Research, Development, and License Agreements - Additional Information (Detail) $ in Thousands	1 Months Ended				3 Months Ended				9 Months Ended		12 Months Ended
	Oct. 31, 2011 USD ($)	Dec. 31, 2008 USD ($) Project	Sep. 30, 2008 USD ($)	Sep. 30, 2006	Sep. 30, 2013 USD ($)	Dec. 31, 2012 USD ($)	Sep. 30, 2012 USD ($)	Mar. 31, 2012 USD ($)	Sep. 30, 2013 USD ($)	Sep. 30, 2012 USD ($)	Dec. 31, 2011 USD ($)	Jun. 30, 2012 USD ($)	May 31, 2012 USD ($)	Jul. 31, 2011 USD ($)	Aug. 31, 2010 USD ($)	Jul. 31, 2010 USD ($)
Glaxo, Smith, Kline
Product Information [Line Items]
Number of programs for research and early clinical development \| Project		4
Collaboration Revenue		$ 10,000			$ 357		$ 357		$ 1,071	$ 1,071
Revenue from milestone payment											$ 12,000
Deferred revenue recognition period					7 years				7 years
Deferred revenue					$ 3,200	$ 4,200			$ 3,200
Glaxo, Smith, Kline \| Expansion
Product Information [Line Items]
Revenue from milestone payment											3,000
Glaxo, Smith, Kline \| Maximum
Product Information [Line Items]
Potential milestone payment					125,000				125,000
Glaxo, Smith, Kline \| Maximum \| Annual net sales milestones achieved
Product Information [Line Items]
Potential milestone payment					60,000				60,000
Astra Zeneca
Product Information [Line Items]
Collaboration Revenue					180		180		540	540
Revenue from milestone payment					$ 573		$ 513		$ 1,738	$ 1,991
Deferred revenue recognition period					50 months				50 months
Deferred revenue					$ 5,700	7,700			$ 5,700
Research collaboration and license agreement period				3 years
Amendment
Product Information [Line Items]
Collaboration Revenue	$ 3,000
Cost of clinical development activities											$ 20,000
Amendment \| Advance the program following completion of Phase 2a
Product Information [Line Items]
Collaboration Revenue						$ 6,000		$ 2,600
Revenue from milestone payment									20,000
Amendment \| Maximum \| Advance the program following completion of Phase 2a
Product Information [Line Items]
Revenue from milestone payment									100,000
Autoimmune Disease \| National Institutes of Health
Product Information [Line Items]
Grants receivable												$ 600
Rheumatoid Arthritis \| National Institutes of Health
Product Information [Line Items]
Grants receivable													$ 400
Skin Autoimmune Inflammation \| National Institutes of Health
Product Information [Line Items]
Grants receivable														$ 600
HBV \| National Institutes of Health
Product Information [Line Items]
Grants receivable															$ 1,400
HPV \| National Institutes of Health
Product Information [Line Items]
Grants receivable																$ 600
ISS Technology \| National Institutes of Health
Product Information [Line Items]
Contract agreement period			5 years
Contract awarded to develop technology			$ 17,000
Hepatic Fibrosis and Cirrhosis \| National Institutes of Health
Product Information [Line Items]
Grants receivable					$ 200				$ 200

Summary of Revenue Recognized under Agreement with GSK (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2008	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2011
Product Information [Line Items]
Total		$ 2,927	$ 2,874	$ 8,404	$ 7,908
Grant revenue		1,700	1,219	3,855	3,188
National Institutes of Health
Product Information [Line Items]
Grant revenue		235	119	730	348
Glaxo, Smith, Kline
Product Information [Line Items]
Initial payment	$ 10,000	357	357	1,071	1,071
Performance of research activities						$ 12,000
Astra Zeneca
Product Information [Line Items]
Initial payment		180	180	540	540
Performance of research activities		573	513	1,738	1,991
Total		753	693	2,278	2,531
National Institute Of Allergy And Infectious Diseases
Product Information [Line Items]
Grant revenue		$ 1,465	$ 1,100	$ 3,125	$ 2,840

Net Loss Per Share - Additional Information (Detail) - shares	3 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Outstanding warrants and equity awards were not included in diluted net loss per share calculation	31,100,000	34,400,000

Option Activity under Stock Plans (Detail) $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended
	Sep. 30, 2013 USD ($) $ / shares shares
Number of Options Outstanding
Beginning balance \| shares	13,806
Options granted \| shares	5,542
Options exercised \| shares	(74)
Ending balance \| shares	16,865
Vested and expected to vest at end of period \| shares	16,272
Exercisable at end of period \| shares	10,977
Weighted-Average Price Per Share
Beginning balance \| $ / shares	$ 3.38
Options granted \| $ / shares	2.71
Options exercised \| $ / shares	1.41
Ending balance \| $ / shares	3.17
Vested and expected to vest at end of period \| $ / shares	3.18
Exercisable at end of period \| $ / shares	$ 3.35
Weighted Average Remaining Contractual Life (In years)
Balance as of September 30, 2013	5 years 4 months 6 days
Outstanding options vested and expected to vest at end of period	4 years 11 months 19 days
Options exercisable at end of period	3 years 4 months 13 days
Aggregate Intrinsic Value
Balance as of September 30, 2013 \| $	$ 310
Outstanding options (vested and expected to vest) at end of period \| $	310
Options exercisable at end of period \| $	$ 307
Unvested
Number of Options Outstanding
Options cancelled \| shares	(2,028)
Weighted-Average Price Per Share
Options cancelled \| $ / shares	$ 3.33
Vested
Number of Options Outstanding
Options cancelled \| shares	(381)
Weighted-Average Price Per Share
Options cancelled \| $ / shares	$ 3.56

Summary of Restricted Stock Units Activity (Detail) - Restricted Stock Units (RSUs) shares in Thousands	9 Months Ended
	Sep. 30, 2013 $ / shares shares
Number of shares
Beginning Balance \| shares	1,755
Granted \| shares	250
Vested \| shares
Forfeited or expired \| shares	(230)
Ending Balance \| shares	1,775
Weighted Average Grant Date Fair Value
Beginning Balance \| $ / shares	$ 4.23
Granted \| $ / shares	1.23
Vested \| $ / shares
Forfeited or expired \| $ / shares	4.23
Ending Balance \| $ / shares	$ 3.81

Fair Value-Based Measurements and Weighted-Average Assumptions (Detail) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average fair value	$ 1.15	$ 3.34	$ 2.43	$ 3.30
Risk-free interest rate	1.90%	0.60%	1.10%	0.50%
Expected life (in years)	5 years 7 months 6 days	4 years	5 years 10 months 24 days	4 years
Volatility	1.50%	1.60%	1.40%	1.60%
Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average fair value			$ 0.93	$ 3.80
Risk-free interest rate			0.20%	0.20%
Expected life (in years)			1 year 3 months 18 days	1 year
Volatility			0.80%	1.60%

Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]
Share Based Compensation	$ 2,845	$ 1,903	$ 10,847	$ 6,294
Research and Development Expense
Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]
Share Based Compensation	1,001	824	3,351	2,565
General and Administrative Expense
Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]
Share Based Compensation	$ 1,844	$ 1,079	$ 7,496	$ 3,729

Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	May 29, 2013	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expiration period				10 years
Options vesting period				4 years
Expected Dividend yield				0.00%
Recognized stock-based compensation expense		$ 1,000		$ 5,100
Stock-based compensation expense		2,845	$ 1,903	10,847	$ 6,294
Total unrecognized compensation cost related to non-vested equity awards		$ 5,000		$ 5,000
Warrants
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Warrants to purchase common stock		12,500,000		12,500,000
Warrants exercised				84,000	4,700,000
Warrants exercisable per share				$ 1.96
Senior Management Group
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected Life (in year)				6 years
All Other Employees
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected Life (in year)				5 years 6 months
Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Aggregate intrinsic value		$ 2,100		$ 2,100
Performance based Vesting Condition
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares underlying stock options and restricted stock units awards with performance-based vesting criteria		2,600,000		2,600,000
2011 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Increase in the aggregate number of shares of common stock authorized for issuance	10,000,000
Non Employee Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense				$ 400
Time Based Vesting Schedule
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total unrecognized compensation cost related to non-vested equity awards		$ 12,100		$ 12,100
Total unrecognized compensation cost, weighted-average vesting period				2 years 11 months 5 days
Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserved and approved for issuance		996,000		996,000
Shares issued to employees				828,414
Shares remaining available for future purchases		167,586		167,586
Employee Stock Purchase Plan \| Current Period One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares issued to employees				129,690

Subsequent Events - Additional Information (Detail) - Subsequent Event $ / shares in Units, $ in Millions	1 Months Ended
	Oct. 30, 2013 USD ($) $ / shares shares
Subsequent Event [Line Items]
Sale of stock, shares \| shares	79,570,000
Public offering net price per share \| $ / shares	$ 1.075
Net proceeds from offering \| $	$ 125
Series B Convertible Preferred Stock
Subsequent Event [Line Items]
Sale of stock, shares \| shares	43,430
Public offering net price per share \| $ / shares	$ 1,075.00